AI-generated summary
The authors report a randomized controlled trial of at-home photobiomodulation (red and near-infrared light) added to standard care for adults with mild-to-moderate COVID-19 symptoms. Patients with up to 7 days of symptoms recovered faster in the treatment group, though the difference was borderline statistically (p = 0.050), and no benefit was seen in patients with longer symptom duration.
- Participants
- 199
- Who or what was studied
- Adults aged 18-65 with COVID-19 and upper respiratory symptoms scored 4-7 on the WURSS-44 severity scale, treated at home
- Wavelengths
- 635, 810 nm
- Limits stated in the abstract
- The primary result for patients with up to 7 days of symptoms was borderline (p = 0.050, hazard ratio confidence interval including 1), and the subgroup with 8-12 days of symptoms was small and showed no significant benefit.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Photobiomodulation therapy (PBMT) using devices to deliver red and/or near-infrared light to tissues has shown promising effects in clinical settings for respiratory diseases, including potential benefits in managing symptoms associated with COVID-19.
Objective
To determine if at-home self-administered PBMT for patients with COVID-19 is safe and effective.
Methods
This was a randomized controlled trial (RCT) carried out at home during the COVID-19 pandemic (September 2020 to August 2021). The treatment group self-administered the Vielight RX Plus PBMT device (635 nm intranasal and 810 nm chest LEDs) and were monitored remotely. Eligible patients scored 4-7 (out of 7) for severity on the Wisconsin Upper Respiratory Symptom Survey (WURSS-44). Patients were randomized equally to Control group receiving standard-of-care (SOC) only or Treatment group receiving SOC plus PBMT. The device was used for 20 min 2X/day for 5 days and, subsequently, once daily for 30 days. The primary end-point was time-to-recovery (days) based on WURSS-44 question 1, "How sick do you feel today?". Subgroup analysis was performed, and Kaplan-Meier and Cox Proportional Hazards analysis were employed.
Results
One hundred and ninety-nine eligible patients (18-65 years old) were divided into two subgroups as follows: 136 patients with 0-7 days of symptoms at baseline and 63 patients with 8-12 days of symptoms. Those with 0-7 days of symptoms at baseline recovered significantly faster with PBMT. The median for Treatment group was 18 days [95% confidence interval (CI), 13-20] versus the Control group 21 days (95% CI, 15-28), p = 0.050. The treatment:control hazard ratio was 1.495 (95% CI, 0.996-2.243), p = 0.054. Patients with symptom duration ≥7 days did not show any significant improvement. No deaths or severe adverse events (SAEs) occurred in the Treatment group, whereas there was 1 death and 3 SAEs requiring hospitalization in the Control group.
Conclusions
Patients with ≤7 days of COVID-19 symptoms recovered significantly faster with PBMT compared to SOC. Beyond 7 days, PBMT showed no superiority over SOC.
Trial Registration
ClinicalTrials.gov NCT04418505.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 635 nm, 810 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Randomized controlled trial, Photobiomodulation, Control group, Confidence interval, Trial registration, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.